HeartBeam Ranked Second Globally in 12-Lead ECG Innovation

HeartBeam Inc. (NASDAQ: BEAT) has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide in 12-lead ECG innovation among 243 companies evaluated in PatentVest's 'Total Cardiac Intelligence' report available at https://ibn.fm/ZuLCr. The medical-technology company, which develops advanced electrocardiogram solutions for remote cardiac care, trailed only GE Healthcare in the global rankings, underscoring its significant position in the competitive cardiac diagnostics landscape.

The recognition highlights HeartBeam's growing influence in the next generation of cardiac monitoring technology and underscores the rapid maturation of the company's proprietary synthesis-ECG system. This technology captures the heart's electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG, representing a significant advancement in portable cardiac monitoring capabilities. The company's intellectual-property foundation was cited as a major reason for its high placement in the global rankings.

HeartBeam's portable non-invasive recorder is intended to record, store, and transfer a patient's 3-Lead electrocardiogram acquired from 5 electrodes. The device is designed for use by adult patients in either clinical settings or at home, though it does not conduct cardiac analysis and requires manual interpretation of non-life-threatening arrhythmias by healthcare professionals. For comprehensive safety information, users can consult the full Instructions for Use or Clinician Portal Manual.

This recognition comes at a critical time for remote healthcare technology, as the global shift toward telemedicine and home-based medical monitoring continues to accelerate. The ranking positions HeartBeam as a significant player in the evolving landscape of cardiac care technology, particularly as demand grows for accessible, portable diagnostic tools that can provide comprehensive cardiac data outside traditional clinical settings. The company's technology represents an important step forward in making sophisticated cardiac monitoring more accessible to patients and healthcare providers alike.

The implications of this recognition extend beyond corporate achievement, potentially influencing how cardiac care is delivered globally. As portable ECG technology becomes more sophisticated and widely available, patients may benefit from earlier detection of cardiac issues and more convenient monitoring options. Healthcare systems could see improved efficiency in cardiac care management, while the broader medical technology industry may experience accelerated innovation in remote monitoring solutions. The ranking validates HeartBeam's approach to cardiac diagnostics and suggests growing market confidence in portable ECG solutions as viable alternatives to traditional hospital-based monitoring systems.